These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 38308627

  • 1. Health care costs and utilization of progressive fibrosing lung disease by underlying interstitial lung disease type.
    Nili M, Steffens A, Anderson A, Brekke L, Grace Johnson M, Veeranki P, Olson AL.
    J Manag Care Spec Pharm; 2024 Feb 03; 30(2):163-174. PubMed ID: 38308627
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Healthcare Resource Utilization and Related Costs in Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A US Claims Database Analysis.
    Olson AL, Hartmann N, Patnaik P, Garry EM, Bohn RL, Singer D, Baldwin M, Wallace L.
    Adv Ther; 2022 Apr 03; 39(4):1794-1809. PubMed ID: 35199282
    [Abstract] [Full Text] [Related]

  • 4. Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis.
    Olson AL, Patnaik P, Hartmann N, Bohn RL, Garry EM, Wallace L.
    Adv Ther; 2021 Jul 03; 38(7):4100-4114. PubMed ID: 34156606
    [Abstract] [Full Text] [Related]

  • 5. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
    Olson AL, Maher TM, Acciai V, Mounir B, Quaresma M, Zouad-Lejour L, Wells CD, De Loureiro L.
    Adv Ther; 2020 Jul 03; 37(7):3292-3298. PubMed ID: 32451950
    [Abstract] [Full Text] [Related]

  • 6. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
    Singer D, Bengtson LGS, Conoscenti CS, Laouri M, Shetty SS, Anderson AJ, Brown KK.
    Ann Am Thorac Soc; 2022 Jul 03; 19(7):1112-1121. PubMed ID: 35015982
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The Burden of Progressive Fibrosing Interstitial Lung Disease: A DELPHI Approach.
    Wuyts WA, Papiris S, Manali E, Kilpeläinen M, Davidsen JR, Miedema J, Robalo-Cordeiro C, Morais A, Artés M, Asijee G, Cendoya D, Soulard S.
    Adv Ther; 2020 Jul 03; 37(7):3246-3264. PubMed ID: 32445186
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study).
    Nasser M, Larrieu S, Boussel L, Si-Mohamed S, Bazin F, Marque S, Massol J, Thivolet-Bejui F, Chalabreysse L, Maucort-Boulch D, Hachulla E, Jouneau S, Le Lay K, Cottin V.
    Respir Res; 2021 May 24; 22(1):162. PubMed ID: 34030695
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Importance of chest HRCT in the diagnostic evaluation of fibrosing interstitial lung diseases.
    Torres PPTES, Rabahi MF, Moreira MADC, Escuissato DL, Meirelles GSP, Marchiori E.
    J Bras Pneumol; 2021 May 24; 47(3):e20200096. PubMed ID: 34076172
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.